Corbus Pharmaceuticals said the FDA cleared its registrational TEMPO-1 study of CRB-701 in second-line oropharyngeal squamous cell carcinoma. The Nectin-4-targe

BWB News TV • 2026-07-28 13:27 UTC • By Billy Odell Tucker-Robinson

Corbus Pharmaceuticals said the FDA cleared its registrational TEMPO-1 study of CRB-701 in second-line oropharyngeal squamous cell carcinoma. The Nectin-4-targeted ADC marks a key pipeline milestone after updated Phase 1/2 data.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly